Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cost of Revenue: 2018-2025

Historic Cost of Revenue for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $28.0 million.

  • Ultragenyx Pharmaceutical's Cost of Revenue rose 33.16% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 34.31%. This contributed to the annual value of $76.7 million for FY2024, which is 69.72% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Cost of Revenue is $28.0 million, which was up 21.69% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Cost of Revenue registered a high of $28.7 million during Q1 2025, and its lowest value of $3.1 million during Q2 2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Cost of Revenue had a median value of $17.5 million in 2024 and averaged $18.3 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Cost of Revenue crashed by 35.98% in 2021 and then spiked by 163.71% in 2022.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Cost of Revenue stood at $3.5 million in 2021, then spiked by 51.58% to $5.3 million in 2022, then spiked by 126.57% to $12.1 million in 2023, then skyrocketed by 40.19% to $16.9 million in 2024, then spiked by 33.16% to $28.0 million in 2025.
  • Its Cost of Revenue stands at $28.0 million for Q3 2025, versus $23.0 million for Q2 2025 and $28.7 million for Q1 2025.